PhRMA

JUNE 14, 2023

The 340B Drug Pricing Program has grown yet again , exceeding $100 billion in sales in 2022 when 340B-priced medicines are measured at wholesale acquisition cost. year-over-year in 2022, continuing a trend in which 340B sales have almost doubled since 2018, outpacing growth of the total U.S. drug market.

Drug Pricing 123

Drug Pricing 123

STAT

FEBRUARY 21, 2023

billion by “abusing” its position in the marketplace and keeping prices high. billion worth of Humira in the Netherlands between 2004 and 2018, when its patents provided a monopoly. The company sold approximately $2.3 Continue to STAT+ to read the full story…

Drug Pricing 241

Drug Pricing 241

STAT

JANUARY 3, 2023

More specifically, 70 of the 93 top-selling drugs covered by the Medicare Part B program – which are typically pricier medicines that are administered by physicians or in hospitals – between 2018 and 2020 would have been subject to inflationary rebates each year, according to the analysis published in JAMA.

Immunity 246

Immunity Immunization Hospitals Drug Pricing 246

STAT

JUNE 4, 2023

The world has changed since 2018 when the Biotechnology Innovation Organization last brought its annual road show to Boston, complete with entrepreneurial boot camps, beer-flowing receptions, and four days of nonstop networking.

Vaccines 249

Vaccines Drug Pricing Drug Development 249

pharmaphorum

MAY 12, 2021

According to market research from 46brooklyn AbbVie has increased the price of Humira by 7.4% Sales have fallen outside of the US because of competition from biosimilars, which have already been on the market in Europe since 2018. No-one from AbbVie was immediately available for comment.

Biosimilars 105

Biosimilars Drug Pricing 105

pharmaphorum

NOVEMBER 27, 2020

Vertex introduced Kalydeco in 2012, and has since followed up with launches of two-drug combinations Orkambi (lumacaftor/ivacaftor) and Symkevi – known as Symdeko in the US – in 2015 and 2018, respectively. Together these drugs cover the CFTR mutations seen in around half of all CF patients.

Labelling 134

Labelling Drug Pricing 134

FDA Law Blog: Biosimilars

JUNE 16, 2023

Kirschenbaum — On May 24, Minnesota enacted the Commerce and Consumer Protection Omnibus Bill, Senate File 2744 ( SF 2744 ), which significantly expands the state’s existing drug pricing activities with serious implications for all drug manufacturers, and particularly generic drug manufacturers.

Drug Pricing 45

Drug Pricing Biosimilars Dosage Documentation 45

HealthPartners

MAY 5, 2021

Understanding pharmacy benefit management and drug pricing The U.S. prescription drug supply chain is extraordinarily complex. It captures, with strong simplification, the web of stakeholders in the prescription drug market and the myriad of contractual agreements that drives the cash flows between them. The result?

Drug Pricing 40

Drug Pricing Mail-Order Pharmacies Pharmaceutical Manufacturing Pharmaceutical Companies 40

Putting Patients First Blog

NOVEMBER 14, 2023

NHC Comments on Request for Information: Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program (PDF) November 13, 2023 Benjamin Stidham, Contract Specialist Centers for Medicare & Medicaid Services U.S. Drug Distribution Data 2019. Rural Policy Brief, 2018(2) , 1-6. 5 Salako, A.,

Drug Pricing 40

Drug Pricing Specialty Pharmacies HIPAA Payment Processing 40

Putting Patients First Blog

SEPTEMBER 7, 2023

Cardiac screening The use of echocardiogram and cardiac MRI in Duchenne increased across most age groups when comparing the time periods 2007-2012, 2013-2017, and 2018-2022 with some age groups having statistical significance. This may be because many clinics temporarily paused doing pulmonary function testing during the COVID-19 pandemic.

Drug Pricing 111

Drug Pricing 111

Pharmaceutical Technology

NOVEMBER 21, 2022

According to the report, five member companies decided to decrease their investment in Japan between 2016 and 2017, four companies changed their investment targets between 2018 and 2020, and one company lowered the priority given to Japan after 2021. The MHLW is currently proposing discussions on the FY2023 drug price revision.

Drug Pricing 69

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 69

Drug Channels

DECEMBER 17, 2020

This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Drug Channels Outlook 2021. Drug pricing perceptions always seem to lag reality. HHS relied in part on a highly misleading ASPE study of 2018 data. Consider HHS's "Most Favored Nation" model for Medicare Part B.

Biosimilars 52

Biosimilars Drug Pricing 52

pharmaphorum

NOVEMBER 21, 2022

It also has an option on global marketing rights to the drug. Also benefiting from the approval is MacroGenics, which previously developed teplizumab before licensing it to Provention in 2018.

Diabetes 116

Diabetes Drug Pricing 116

Pharmaceutical Technology

NOVEMBER 21, 2022

According to the report, five member companies decided to decrease their investment in Japan between 2016 and 2017, four companies changed their investment targets between 2018 and 2020, and one company lowered the priority given to Japan after 2021. The MHLW is currently proposing discussions on the FY2023 drug price revision.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 52

pharmaphorum

FEBRUARY 17, 2021

Few details about Haven emerged after the new venture was announced to the public in January 2018 and the Haven brand name did not appear until about a year later. CVS Health, Walmart, Cardinal Health and Express Scripts were among those affected. He told his guests, “We are not happy with healthcare costs and want to help.”

Online Pharmacies 126

Online Pharmacies Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 126

Pharmaceutical Technology

MARCH 10, 2023

Consequentially, the five-year average price trend in Lebanon for all medicines has increased to 1,123%. GlobalData reviews the key events leading up to these current price trends in Lebanon. As this reduction of subsidies coincided with the weakening of the Lebanese pound, it resulted in further heavy price increases.

Drug Pricing 52

Drug Pricing Packaging 52

Drug Channels

JUNE 9, 2020

The 340B Drug Pricing Program has logged another year of incredible growth. According to data provided to Drug Channels by the Health Resources and Services Administration (HRSA), discounted 340B purchases were at least $29.9 That figure is an astonishing 23% higher than its 2018 counterpart. billion in 2019.

Drug Pricing 40

Drug Pricing Hospitals 40

FDA Law Blog: Biosimilars

SEPTEMBER 23, 2024

Hatch Foundation’s For cheap generic drug prices, you can thank 40 years of Hatch-Waxman We Work For Health’s Hatch-Waxman Act: Celebrating 40 Years of a Balanced and Innovative Drug Ecosystem Tradeoffs’ Race to the Bottom Series FDA CDER Conversations – 40th Anniversary of the Generic Drug Approval Pathway The U.S.

Dosage 59

Dosage Drug Pricing 59

Express Pharma

SEPTEMBER 6, 2023

Not only will this precipitate into lower treatment costs and ensure equitable biopharma access for Indian patients, but could also peg Indian pharma companies to become global market leaders in the biosimilars segment and effect a major change in drug pricing standards. appeared first on Express Pharma.

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing 59

Safe Biologics

FEBRUARY 1, 2024

In 2018, the project was put on hold for data gathering. Over the years, the WHO has attempted to evaluate the BQ: a provisional implementation of the programme was suggested in 2016, and in 2017 a pilot BQ project was discussed. The ASBM would be interested in knowing the status of these approaches.

Biosimilars 130

Biosimilars Documentation Drug Pricing 130

pharmaphorum

SEPTEMBER 8, 2020

Published 17 September 2018. 6 Forbes, ‘Biologic Medicines: The Biggest Driver of Rising Drug Prices’. Available from: [link] [Last accessed: September 2020]. 5 Bloomberg, ‘These Are the Economies With the Most (and Least) Efficient Health Care’. Last accessed: 30 September 2020]. Published 8 March 2019.

Biosimilars 99

Biosimilars Drug Pricing Chemotherapy Vaccines 99

pharmaphorum

FEBRUARY 18, 2021

Drug prices to plummet in wave of expiring patents”. Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. RESULT: Humalog is still Lilly’s second top-selling drug with nearly $3 billion in sales in 2018.

Prescription Filling 52

Prescription Filling Drug Pricing Biosimilars Compounding 52

Pharmaceutical Technology

SEPTEMBER 26, 2022

Innovative drug development can be costly and risky due to clinical trial attrition of unproven drugs, but can provide a high return on investment when successful. On 27 March 2018, GlaxoSmithKline (GSK) (Brentford, UK) announced that it had reached an agreement with Novartis for the buyout of Novartis’ 36.5%

Biosimilars 64

Biosimilars Drug Development Vaccines Dosage 64

Big Molecule Watch

JANUARY 25, 2024

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program.

Biosimilars 45

Biosimilars Labelling Drug Pricing 45

pharmaphorum

FEBRUARY 23, 2022

The case concerns actions allegedly taken by Servier between 2005 and 2007, in which the pharma company entered into “pay for delay” agreements with four generic drugmakers to stall competition for its blockbuster anti-hypertension drug perindopril (brand name Coversyl).

Drug Pricing 52

Drug Pricing 52

Proxsys Rx

MARCH 23, 2023

It’s a particularly attractive solution, in a time of high inflation (particularly inflated drug prices) for patients with high deductibles or no insurance. The cost of prescription non-adherence to the community at large — which ultimately pays for uncompensated care (particularly for hospital readmissions) — is staggering.

Drug Pricing 52

Drug Pricing Hospitals Prescription Filling Dosage 52

HealthPartners

JULY 21, 2021

Represents 2018 performance, latest published figure. For example, members can compare drug prices at pharmacies or find a network provider. Represents 2018 performance, latest published figure. Our consistently low pharmacy costs per member per month (PMPM) testify to it. Cost performance (PMPM) of leading PBMs.

Biosimilars 52

Biosimilars Specialty Pharmacies Mail-Order Pharmacies Health Insurance Companies 52

Proxsys Rx

APRIL 19, 2024

In response, The Centers for Medicare & Medicaid Services ( CMS ) issued a proposed remedy for covered entities whose 340B payments were wrongly reduced in calendar years 2018-22. The ruling is an estimated 19,247 words long, or just over 37 pages, printed in single-spaced 10-point Arial.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Drug Pricing Packaging 52

Proxsys Rx

JANUARY 12, 2024

In response, The Centers for Medicare & Medicaid Services ( CMS ) issued a proposed remedy for covered entities whose 340B payments were wrongly reduced in calendar years 2018-22.

Specialty Pharmacies 52

Specialty Pharmacies Hospitals Drug Pricing Packaging 52

pharmaphorum

JUNE 10, 2021

Against this backdrop, there has been substantial public debate about rising drug prices forced on consumers, including the trite notion that pharmaceutical companies are being “greedy” and seeking to price-gouge the public. The truth about rising drug prices is more nuanced and merits exploration.

Drug Pricing 105

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Vaccines 105

Pharmaceutical Technology

JUNE 2, 2023

In a bit to challenge the market dominance of AbbVie’s Humira (adalimumab), the online pharmacy Cost Plus Drugs, owned by billionaire Mark Cuban has announced a plan to market Coherus Biosciences’ biosimilar Yusimry (adalimumab-aqvh), Cost Plus Drugs will be offering Yusimry at $569 per unit, excluding shipping and dispensing charges.

Biosimilars 52

Biosimilars Online Pharmacies Drug Pricing Communication 52

Pharmaceutical Technology

JANUARY 6, 2023

Last week, Novartis announced plans to pay $245 million to end a pay-for-delay legal battle that started in 2018. In this most recent settlement, the drug company faced allegations of colluding with the generics company Par Pharmaceuticals to violate antitrust laws. These actions allegedly led to the extension of Novartis’ patents.

Documentation 97

Documentation Hospitals Dosage Drug Pricing 97

STAT

MARCH 5, 2025

Chronic diseases, such as diabetes, cancer, and cardiovascular disease, pose one of the most significant health threats to Americans today. The share of Americans with multiple chronic conditions increased from 21.8% in 2001 to 27.2% In 2022, these illnesses claimed the lives of 1.9 Read the rest…

Drug Development 276

Drug Development Diabetes Drug Pricing 276

STAT

JULY 7, 2023

The remedy accounts for four years of underpayments to hospitals that participate in the 340B drug discount program. The Trump administration dramatically reduced Medicare payments for discounted drugs in 2018, but the Supreme Court found they didn’t follow the proper procedure and that the payment scheme was illegal.

Hospitals 245

Hospitals Drug Pricing 245

Ramblings of a pharmacist

FEBRUARY 20, 2022

At the same time, we see our neighbors complain about rising drug prices, and the rising cost of health insurance: Restaurateurs complain a lot about GrubHub and their seller fees, their menu stealing, and their ghost kitchens. We complain about DIR fees. About financial middlemen who add no value but extract plenty.

Health and Personal Care Stores 40

Health and Personal Care Stores Independent Pharmacies Drug Pricing Packaging 40

STAT

OCTOBER 7, 2024

… Former President Trump is backing off his support for a controversial drug pricing plan that struck fear into the hearts of pharmaceutical executives during his first term , STAT reports. Meanwhile, we have assembled another menu of tidbits for you to peruse as you start another journey. Your cards and notes are appreciated.

Drug Pricing 276

Drug Pricing Vaccines 276